Improvement in serum eosinophilia is observed in clinical responders to ustekinumab but not adalimumab in inflammatory bowel disease - Top-Institutions - MDSpire

Improvement in serum eosinophilia is observed in clinical responders to ustekinumab but not adalimumab in inflammatory bowel disease

  • By

  • Emily C L Wong

  • Parambir S Dulai

  • John K Marshall

  • Vipul Jairath

  • Walter Reinisch

  • Neeraj Narula

  • January 13, 2025

  • 0 min

Share

Top Institutions in Gastroenterology

Brief introduction explaining scope and methodology.

  • #1

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Gastroenterology
    • Immunology
    • Clinical Research

  • #2

    Mount Sinai Health System
    Mount Sinai Health System

    New York, NY

    Key Differentiators

    • Gastroenterology
    • Immunology
    • Inflammatory Bowel Disease

  • #3

    Cleveland Clinic
    Cleveland Clinic

    Cleveland, OH

    Key Differentiators

    • Gastroenterology
    • Immunology
    • Clinical Trials

  • #4

    University of California, San Francisco (UCSF) Medical Center
    University of California, San Francisco (UCSF) Medical Center

    San Francisco, CA

    Key Differentiators

    • Gastroenterology
    • Immunology
    • Translational Research

  • #5

    Johns Hopkins Medicine
    Johns Hopkins Medicine

    Baltimore, MD

    Key Differentiators

    • Gastroenterology
    • Immunology
    • Clinical Research

Original Source(s)

Improvement in serum eosinophilia is observed in clinical responders to ustekinumab but not adalimumab in inflammatory bowel disease

  • by Emily C L Wong, Parambir S Dulai, John K Marshall, Vipul Jairath, Walter Reinisch, Neeraj Narula

  • January 13, 2025

Related Content

Risk of intestinal involvement in mucocutaneous-onset Behçet’s disease: data from the AIDA network registry

This Week’s Biopharma News: Amgen Deepens US Manufacturing Push

The company adds $300 million to its Puerto Rico biologics site as Pfizer reports Phase 3 myeloma data, J&J advances a dual-pathway IBD antibody, and BioNTech streamlines production

  • May 12, 2026

  • 7 min
Sex-related peripheral immune profile in ulcerative colitis: links to fatigue